This implies that passive immunization with tau antibodies is usually a viable therapeutic goal and which the CSF standard of p-tau262/356 or on the microtubule binding domain (MTBD) can function a practical biomarker of tau pathology to monitor tau therapeutics in medical trials.Their Tale laid the muse for precisely what is shaping up to become a